Evaluation of Point-of-Care Testing for Creatinine, Estimated Glomerular Filtration Rate, and Potassium in a Diverse United Kingdom Population
In brief
Epoc kidney testing identified chronic kidney disease with 99% specificity
In 310 adults, including a diverse UK population, Epoc measurements agreed more closely with laboratory results than NovaMax Pro and classified chronic kidney disease with 99% specificity; NovaMax Pro was more sensitive at 94%. Epoc potassium readings differed between capillary and venous samples, so device choice and sampling method matter when using these tests in practice.
- Journal
- The journal of applied laboratory medicine (Q2)
- Published
- 16 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Rouvick Mariano Gama, Amy Packham-Smith, Abigail Clark, Emmanuel Joson, Nirmaladevi Santhosh, Danilo Nebres, et al.
- PMID
- 43037169
- DOI
- 10.1093/jalm/jfag170
Why clinicians should know about it
- Picked for Biochemistry (medical) (top studies of the week, 22 November 2026): Direct analytical validation of renal point-of-care assays
Abstract
BACKGROUND: Point-of-care testing (POCT) for renal function has the potential to enhance access to kidney disease management. However, real-world validation of renal POCT devices in people with chronic kidney disease (CKD) remains limited, particularly in diverse populations. METHODS: We conducted a prospective cohort study to evaluate agreement between 2 renal POCT devices for serum creatinine (SCr), estimated glomerular filtration rate (eGFR), and potassium. Adults with and without CKD underwent capillary and venous sampling on POCT devices, with comparison to reference laboratory standards. Creatinine was measured using NovaMax Pro and Epoc Blood Analysis System (Epoc); potassium was assessed with Epoc. Agreement was evaluated using correlation coefficients, bias, precision, accuracy, and Bland-Altman analysis. Sensitivity and specificity for detecting CKD (eGFR < 60 mL/min/1.73 m2) were evaluated. RESULTS: There were 310 participants included; 49% were from ethnic minority groups (29% Black; 14% South Asian). Both POCT devices demonstrated strong correlation with laboratory SCr and eGFR. NovaMax Pro systematically overestimated SCr, particularly at higher concentrations, whereas Epoc showed greater precision and accuracy. No significant differences were observed between capillary and venous samples. eGFR bias was modest for both devices. Sensitivity was higher with NovaMax Pro (94%), while specificity was higher with Epoc (99%). Epoc potassium measurements differed significantly between capillary and venous samples (P < 0.001). CONCLUSION: Epoc demonstrated superior overall analytical agreement with laboratory SCr and performance for CKD classification, compared with NovaMax Pro. Device-specific biases and potassium variability highlight the importance of sampling technique, clinical context, and intended use when implementing renal POCT.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.